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Abstract: 
Background: No prognostic classification is currently used for patients treated with systemic 
therapies for Hepatocellular Carcinoma (HCC).  
Methods: We retrospectively analyzed data from patients treated with sorafenib for HCC 
from five centers in France and in the United Kingdom. The training set comprised data from 
two centers and the validation set from three. Variables independently associated with 
Overall Survival (OS) in the training set were used to build the SAP (Sorafenib Advanced HCC 
Prognosis) score. The score was tested in the validation set, then compared with other 
prognostication systems.  
Results: The training set and validation set included 370 and 468 patients respectively. In the 
training set, variables independently associated with OS in multivariable analysis were: 
performance status >0, AFP >400ng/mL, tumor size >7cm, bilirubin >17µmol/L and albumin 
<36g/L. The SAP score was built giving one point to each abnormal variable, and 3 classes 
were constructed. The SAP score was significantly associated with OS in the training set, with 
median OS of 14.9 months for SAP A, 7.2 months for SAP B and 2.5 months for SAP C 
(P<0.001). In the validation set, the SAP score was significantly associated with OS, and 
showed greater discriminative abilities than BCLC and ALBI. However, the HAP score showed 
greater discriminative abilities than the SAP score. 
Conclusion: In European patients treated with sorafenib, the HAP was the most discriminant 
prognostic score and may facilitate stratification in trials and inform clinical decision making.  
Abstract word count: 237 
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Introduction 
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide [1]. 
Many therapeutic interventions are available for HCC, ranging from curative (liver 
transplantation, resection, ablative treatments) to palliative options (transarterial 
treatments, systemic treatment) [2,3]. Sorafenib remains the current standard of care for 
advanced disease [4], with regorafenib recently shown active after first-line sorafenib [5]. 
Many prognostic classifications have been proposed for HCC [2,6–10], and some studies 
have compared the different scores [11,12]. However, most of the classifications addressed 
the prognosis across a wide range of clinical settings, and some are directly linked to a 
recommended treatment strategy according to stage. To address the prognosis with more 
accuracy within treatment groups, alternative prognostic scores including HAP and ART were 
developed in the setting of transarterial (chemo) embolization (TA(C)E) to enable selection 
of patients for therapy at baseline and after first treatment  [13–17]. However, only a few 
studies have specifically addressed prognostic stratification in the advanced stage [18–20], 
and their application has been limited in clinical practice. 
Developing a clinically relevant prognostic score for patients treated with systemic therapies 
might support more robust clinical decisions and enable better stratification within clinical 
trials. We therefore aimed to develop and validate a new score, focusing on patients treated 
with sorafenib, with the objective to keep the score simple, reproducible and objective to 
allow direct translation into clinical practice.   
Methods: 
Patients: 
We retrospectively collected data from patients treated with sorafenib for HCC from five 
centers in the United Kingdom and France. All consecutive patients treated with sorafenib 
for HCC were entered in the databases. Relevant authorizations were obtained from 
institutional and ethical review boards for use of the data. Data was acquired under an 
ethically approved protocol (REC reference 12/LO/1088). Data collected at initiation of 
sorafenib included age, gender, cause of underlying liver disease, previous treatment for 
HCC, presence of extrahepatic spread, presence of macrovascular invasion, performance 
status, alpha-fetoprotein, prothrombin time or International Normalized Ratio (INR), 
albumin, bilirubin, ascites and encephalopathy (as coded by centers for the Child-Pugh 
classification), BCLC classification and Child-Pugh score.  
 
Statistical analysis: 
Statistical analyses and graphs were performed on R statistical software version 3.1.1 (2014-
07-10). Overall survival (OS) was calculated from the start of treatment with Sorafenib to 
death, survival curves were estimated with the Kaplan-Meier approach and compared with 
Log-Rank tests. A p value < 0.05 was considered as statistically significant for all analyses.  
Data from two centers were considered as a training set, and data from three other centers 
as a validation set. 
With our training dataset, a Cox-regression multivariable model was fitted on the OS to 
select which variables were used to calculate the new score. Continuous variables were 
dichotomized using the Receiver-Operating Curve (ROC) procedure. The score was then 
calculated attributing 1 point to the worst class of each binary and independently significant 
covariate and grouping patients into a 3-class system, named Sorafenib Advanced HCC 
Prognostic (SAP) score. 
Then, we used the validation dataset to estimate performance metrics and to compare the 
SAP score with several existing prognostic scores that we were able to calculate from our 
database: BCLC, ALBI and HAP [2,8,13]. The HAP score is calculated giving 1 point when the 
following conditions are met: Albumin < 36 g/dl, AFP > 400 ng/ml, bilirubin > 17 μmol/l or 
maximum tumour diameter >7 cm, then grouping in 4 classes: HAP A if 0 point, HAP B if 1 
point, HAP C if 2 points, HAP D if >2 points. We used goodness of fit parameters of each Cox 
model fitting OS to approximate homogeneity of each scoring system: a higher log-likelihood 
ratio (LR) and a lower Akaike Information Criterion (AIC) indicates a better goodness of fit 
and so a higher homogeneity. Relative likelihoods between models in order to represent the 
probability that the score with the higher AIC minimizes information loss as effectively as the 
score with the lower AIC, and is interpreted as a P value for the comparison of both AIC. In 
opposition with AIC, LR depends on the number of classes assessed, we analyzed the original 
scores and also reduced the HAP score to a 3-class system by combining HAP groups A and B. 
Monotonicity and discriminatory ability of each scoring system were assessed using the Cox 
OS regression models with the Harrel’s C statistics as discriminative indicator and the linear 
predictor to compute Area Under the receiver operating Curve (AUC) at 6, 12, and 24 for 
each scoring system. These discriminative performance metrics were presented with 95% 
confidence intervals computed with a 2-thousand resampling bootstrap procedure.     
Results: 
Patient characteristics 
From February 2003 to August 2014, 370 patients were treated with sorafenib and included 
in the training set (all consecutive patients), and 468 patients were included in the validation 
set (all consecutive patients with data available for calculation of the SAP score). The 
characteristics of the cohort are presented in Table 1. The median follow-up was 29.0 
months [95% Confidence Interval (CI): 21.4-36.6], with 358 patients (76.5%) dead at last 
follow-up and 43.7 months [95% CI: 38.8-48.6] with 330 (89.2%) dead at last follow-up, in 
the training and validation sets, respectively. 
 
Construction of the SAP score in the training cohort 
Results from the Cox-regression model for OS are presented in Supplementary Table S1. 
Variables associated with OS in univariable analysis were albumin, bilirubin, previous 
treatment for HCC, performance status (PS), tumor size, alpha-fetoprotein (AFP) and 
macrovascular invasion. We performed ROC analysis to dichotomize continuous variables. 
Results of the ROC analysis are shown in Supplementary Figure 1. The following thresholds 
were chosen, based on their clinical relevance, their previous use in other classifications, the 
adequate power of discrimination in the ROC analysis and the fact that each split the 
population almost by half: >7cm for size, <36g/L for albumin, >17µmol/L for bilirubin and 
>400ng/mL for AFP. The chosen thresholds were associated with OS in univariable Cox-
regression analysis (Supplementary Table S1). 
We then performed multivariable Cox-regression analysis in the training set, testing the 
variables found positive in univariable analysis (Supplementary Table S1). Five factors were 
found to be independently associated with OS in multivariable analysis: size >7cm, albumin 
<36g/L, bilirubin >17µmol/L, PS >0 and AFP >400ng/mL, with Hazard Ratios between 1.34 
and 1.82. Due to similar Hazard Ratios, we then attributed one point to each of these 
abnormal values, and constructed a 3-class score, named SAP: SAP A if score was 0 or 1, SAP 
B if score was 2 or 3 and SAP C if score was 4 or 5. The SAP score was significantly associated 
with OS in the training set (Supplementary Table S2 and Figure 1A, log-rank P<0.001).  
 
Validation of SAP in the validation set, and comparison with alternative scores 
As in the training set, the SAP score was significantly associated with OS in the validation set 
(Supplementary Table S2 and Figure 1B, log-rank P<0.001 overall, and every comparison 
between 2 classes P<0.001).  
In the validation set we compared the performance of SAP with other scores: BCLC, HAP and 
ALBI. Of note, 409 (87%) patients were BCLC C as might be expected for this patient 
population, and only 55 and 4 patients were BCLC B and D respectively. For ALBI, there were 
only 26 patients (5.6%) in the grade 3 group. BCLC was prognostic (Supplementary Table S2 
and Figure 1D, log-rank P<0.001 overall, and every comparison between 2 classes P<0.001) 
as was HAP (Supplementary Table S2 and Figure 1E and 1F, log-rank P<0.001 overall, p=0.030 
for HAP A vs HAP B, p=0.001 for HAP B vs HAP C and P<0.001 for HAP C vs HAP D). ALBI was 
also prognostic, although comparison between grade 2 and 3 was not statistically significant, 
probably due to low numbers of grade 3 patients (Supplementary Table S2 and Figure 1C, 
log-rank p<0.001 overall, p<0.001 for ALBI grade 1 vs 2 but p=0.068 for ALBI grade 2 vs 3). 
Similar results were seen when we focused on the population of ideal candidates for 
sorafenib treatment, namely Child-Pugh A patients with BCLC B or C stage (Supplementary 
Table S2).  
Due to the lower number of patients in HAP A and B classes, and in order to compare 3-class 
scores, HAP A and HAP B were also grouped for further analysis (Table 2). The SAP score 
seemed superior to BCLC and ALBI, as illustrated by higher homogeneity (higher log 
likelihood) and by lower loss of information (lower AIC, with significant relative likelihood). 
Conversely, the SAP score appeared inferior to HAP, either when assessed as a 3-class score 
or as a 4-class score, according to all parameters tested. Overall, the 4-class HAP score had 
the best performance with the highest Log likelihood ratio and Harrell’s C statistics, the 
lowest AIC criterion, and the highest AUC at all three survival points.  
Finally, we focused on the worst prognostic class of each score in the validation set. Results 
are presented in Supplementary Table S3. The worst class of every classification was 
associated with low median OS and low 6- and 12-months survival. However, the number of 
patients in the worst class was very low for ALBI and BCLC, and the ability to predict the 6-
months survival for a patient in the worst class as compared with the others classes was 
higher and significant for SAP and HAP only. The HAP D class represented almost a fifth of 
the population, and had a median OS of 3.8 months [95%CI: 3.4-4.2], and 6- and 12-months 
survival rates of 27% and 15%, respectively.   
 
  
Discussion 
We developed and validated a new prognostic score specific for HCC patients treated with 
systemic therapy, and more specifically the current first-line treatment, sorafenib. The aim 
was to construct a clinically-relevant score, easy to use by clinicians, and able to accurately 
predict the prognosis, that would support clinical decision making and aid stratification in 
clinical trials. The SAP score is easy to calculate from the characteristics readily available for 
treatment decision in HCC, namely patient’s performance status (PS), liver function tests 
(albumin and bilirubin) and relevant tumor characteristics (tumor size and AFP). This new 
score showed better discriminatory abilities than BCLC and ALBI scores. However, the score 
appeared very similar to the HAP score (partly by design, but mainly due to the same 
variables being independently associated with OS in this population) but was inferior to the 
HAP score in terms of discriminatory abilities. The HAP score was originally constructed for 
patients treated with TA(C)E, but appeared in this study to have equivalent prognostic 
abilities in this population of more advanced cases. 
Many prognostic scores have been developed for HCC [2,6–9,13]. However, some 
classifications are designed to guide the treatment strategies (as the BCLC and the Hong 
Kong Liver Cancer classifications), rather than to provide accurate prognostic information 
[2,9]. Others have used subjective criteria (such as the >50% liver involvement in the Okuda, 
CLIP and other classifications). The ALBI grade, which was recently developed, focusses only 
on liver function and in our study, despite significant prognostic abilities, the ALBI grade 
showed lower discriminative abilities as compared to SAP or HAP, emphasizing the need to 
incorporate some tumoral characteristics for optimal prognostication. Currently, there is no 
consensus on the criteria required for stratification in clinical trials and the SAP or HAP 
scores provide a potential means to do this.  
We chose a pragmatic, yet statistically robust approach in the development of the SAP score 
so that the score used clinically-relevant thresholds. The ROC analysis was strongly 
supportive of the 7-cm size threshold, but other thresholds could have been chosen for 
bilirubin, albumin or AFP, due to a relative plateau. However, we believe that such easy-to-
remember thresholds based on limits of the normal range, already used in the HAP and 
Child-Pugh scores, will facilitate easier translation into clinical practice, while diminishing 
only moderately prognostic abilities. Linear predictors, even when translated into 
nomograms, often encounter difficulties for wide adoption into clinical practice. This is well 
illustrated by the ALBI score, which was developed as a linear predictor, but was translated 
into three grades for easier use in the clinic while maintaining advantage over the Child-Pugh 
score [8,21]. It might appear surprising that neither macrovascular invasion nor extra-
hepatic spread were found prognostic in this study. One explanation that we can propose is 
that while in the overall population of HCC macrovascular invasion and extra-hepatic spread 
do have strong prognostic value, when we consider the more advanced population of 
patients treated with sorafenib, this value is less prominent. As regards to extra-hepatic 
spread, the prognostic value has frequently been studied grouped with macrovascular 
invasion. In this cohort of patients treated with sorafenib, extra-hepatic spread by itself was 
not a prognostic factor. Interestingly, it was also not prognostic in the validation cohort (data 
not shown). As regards to macrovascular invasion, the prognostic value disappeared in 
multivariable analysis, suggesting that other factors correlated with macrovascular invasion 
(AFP level, size of the lesion, frequent hepatic dysfunction…) might be more directly 
prognostic that macrovascular invasion itself. 
At least three other prognostic scores were proposed in the setting of HCC  treated with 
systemic therapies [18–20]. The NIACE score focused on the BCLC C population [18]. The 
score incorporates 5 variables: number of tumors ≥3, infiltrative tumor, AFP ≥200ng/mL, 
Child-Pugh B, and PS ≥1. The calculated score ranges from 0 to 7. However, the variable 
“infiltrative tumor” might be viewed as subjective, and no grouping in classes was proposed, 
thus limiting the applicability of the score. We were not able to test the NIACE score in our 
cohort because only a few of the databases had the “infiltrative tumor” criterion recorded. 
The score proposed by Choi et al still retains the subjective “CLIP-morphology”, provides a 
linear score and is more challenging to implement in the clinic [19]. The Japan Red Cross 
score, despite interesting prognostic abilities, uses des-γ-carboxy prothrombin, which is not 
commonly available in western clinical practice, and also uses the subjective >50% liver 
involvement criterion [20]. We believe that these characteristics might explain the lack of 
adoption of such classifications in clinical practice, and that the limitations are overcome by 
the SAP and HAP scores. Moreover, the HKLC group developed an alternative system to the 
BCLC. We were not able to test this system in our series because it uses the variable extra-
hepatic vascular invasion, while our databases did not distinguish the extent of 
macrovascular invasion. However, the HKLC system was developed more as a way to 
propose alternative treatment strategies rather than a better prognostic system. 
After developing the SAP score in the training cohort, we validated it in the validation set, 
and showed benefit over BCLC and ALBI. However, despite having been developed in 
another context, the HAP score showed better characteristics, with better homogeneity and 
higher discrimination. This could be explained by the exclusion of the only subjective 
parameter of the SAP score, PS. Indeed, the use of PS in the BCLC classification has been the 
subject of controversy [22,23]. Our analysis illustrates the fact that every score should be 
tested in a separate validation cohort: while the inclusion of PS significantly improved the 
results in the training set, its use in the validation set diminished its performance compared 
to the HAP score. The HAP score thus offers the advantages of being totally objective, easy-
to-use, and we would recommend its use in preference to the SAP score. The HAP D class 
defined a significant proportion (20.4%) of the population with a poor prognosis (median OS 
of 3.8 months, 6-months OS of 26% and 12-months OS of 15%), for which the benefit of 
sorafenib is questionable. Interestingly, the previously reported median survival of HAP D 
patients treated with TA(C)E was 3.6 months suggesting that HAP D defines a poor 
prognostic group regardless of therapy [13].  
Our analysis has some limitations: First, the analysis was retrospective and should be 
validated in prospective studies, second, the results were obtained in a European population 
and require validation in other populations, and finally we were not able to compare it with 
the NIACE and HKLC classifications. 
In conclusion, we have developed a new prognostic score for patients treated with systemic 
therapies, but shown that the HAP score is superior in this setting. After appropriate 
validation in confirmatory cohorts, we would recommend the following use of HAP score in 
the context of systemic therapies: HAP A/B vs C could be used for stratification in clinical 
trials, while the benefit/risk ratio of sorafenib in the HAP D population should be questioned 
in view of the very low survival of this population. 
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Table 1: Characteristics of the cohorts 
Parameter Training set (N=370) Validation set (N=468 
with data for SAP) 
Gender: male 90.2% 84.8% 
Median age (range) 67 (34-89) 67 (17-84) 
Cirrhosis 73.9% (N =306) 81.4% (N =208) 
Median albumin value, g/L (range) 
- Albumin < 36g/L 
36 (19-54) 
181 (49.7%) (N =364) 
38 (18-61) 
168 (35.9%) 
Median bilirubin value, mcmol/L 
(range) 
- Bilirubin >17mcmol/L 
17 (3-436) 
 
169 (46.3%) (N =365) 
15 (3-533) 
 
206 (44.0%) 
Child-Pugh class A 257 (75.8%) (N =339) 362 (77.4%) 
Etiology of underlying liver disease 
(some patients might have several): 
- Alcohol 
- HBV 
- HCV 
- Metabolic Syndrome or 
Hemochromatosis 
- No known underlying liver disease 
 
 
206 (55.7%) 
24 (6.5%) 
72 (19.5%) 
148 (40.0%) 
 
66 (17.8%) 
(n=365) 
 
160 (43.8%) 
38 (10.4%) 
59 (15.3%) 
103 (28.2%) 
 
83 (22.7%) 
Previous treatment for HCC 160 (52.3%) (N =306) 203 (43.4%) (N =370) 
Performance status >0 161 (43.8%) (N =368) 308 (65.8%) 
Median size of the largest liver lesion, 
mm (range) 
- Size >7cm 
60 (0-250) 
 
151 (40.8%) 
67 (0-300) 
 
200 (42.7%) 
Extra-hepatic Spread 133 (44.4%) (N =360) 124 (26.5%) 
Macrovascular invasion: 143 (39.8%) (N =359) 192 (41.0%) 
Median AFP, ng/mL (range) 
- AFP >400ng/mL 
121 (0-849,553) 
150 (41.0%) 
109 (1-690,000) 
178 (38.0%) 
BCLC stage: 
- A 
- B 
- C 
- D 
(n=362) 
4 (1.1%) 
68 (18.8%) 
263 (78.2%) 
7 (1.7%) 
 
0 (0%) 
55 (11.8%) 
409 (87.4%) 
4 (0.9%) 
 
 
 
Table 2: Comparison between scores in the validation set. A higher log likelihood ratio 
indicated greater homogeneity, a higher Harrell’s C statistics greater discriminative abilities, 
a lower Akaike Information Criterion (AIC) indicates lower loss of information. 
 Log 
likeliho
od ratio 
Harrell’
s C 
statisti
cs 
Akaike 
Inform
ation 
Criteri
on 
(AIC) 
Relative 
likelihood 
of the score 
equivalence 
of AIC vs 
SAP 
Relative 
likelihood 
of the score 
equivalenc
e of AIC vs 
HAP 4 
classes 
AUC 6 
mont
hs 
AUC 
12 
mont
hs 
AUC 
24 
mont
hs 
SAP 77.5 0.640 
[0.614-
0.667] 
3683  0.03 0.699 
[0.655
-
0.741] 
0.675 
[0.628
-
0.721] 
0.732 
[0.669
-
0.789] 
ALBI 25.7 0.595 
[0.566-
0.625] 
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Figure Legends: 
Supplementary Figure: Receiver Operating Characteristics curves used for the 
dichotomization of continuous variables. 
Figure 1: OS according to SAP score in the training set (A) and in the validation set (B), and 
according to ALBI grade (C), BCLC (D), HAP as a 4-class (E) or 3-class (F) score in the validation 
set. 
 
 
